Physician profile
Mark E Ladner
NPI 1487753562
$2,278.56
in general payments reported to CMS, 2019-2025
13 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $57.98 · 2022: $31.88 · 2023: $496 · 2024: $243 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $455.09 | 2019-2025 | Spravato, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $378.38 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $369.98 | 2020-2025 | Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $220.03 | 2025 | Auvelity |
| Neurocrine Biosciences, INC. | $133.00 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.88 | 2025 | Caplyta |
| Allergan, INC. | $125.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $124.99 | 2019 | |
| Abbvie INC. | $123.78 | 2024 | |
| Bioxcel Therapeutics, INC. | $97.16 | 2023 | Igalmi |
| Biogen, INC. | $89.39 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $17.90 | 2022 | |
| Boston Scientific Corporation | $13.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ladner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.